Navigation Links
DATATRAK CTO Elected as CDISC Advisory Board Chair-Elect

CLEVELAND, Feb. 5, 2013 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced Chris Wilke , DATATRAK's Chief Technology Officer, was elected as the CDISC Advisory Board's (CAB) Chair-Elect. 


"We are very pleased to have Chris Wilke as a member of the CDISC Advisory Board's leadership team. His many years of industry experience will add immense value to this group and will further promote our vision to inform patient care and safety through higher quality medical research," said Dr. Rebecca Kush , President and CEO, CDISC.

"Standards are key to effective sharing of clinical research data and ultimately, improving patient health," stated Chris Wilke , DATATRAK's CTO.  "After serving as a member of the Advisory Board for two years, I am excited to take a more active role in furthering CDISC's mission to develop and support global, platform-independent data standards."

As a Charter Platinum Member of CDISC, DATATRAK has a long history of supporting CDISC and its mission to define and implement standards industry-wide.  The Company currently holds CDISC Registered Solution Provider (RSP) status in the following categories:

  • Define.XML
  • LAB
  • Operational Data Model
  • Study Data Tabulation Model


DATATRAK is the leader of unified eClinical® technologies and related services for the clinical trials industry.  Using the DATATRAK ONE™ multi-product, cloud-based clinical research platform, DATATRAK's Clinical and Consulting Services™ group assists clients in conducting Phase I-IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements.  For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on November 14, 2012 announcing its results for the three-month period ending September 30, 2012. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DATATRAK November Industry Events
2. DATATRAK International, Inc. Investor Presentation Now Available for On-demand Viewing at
3. DATATRAK International, Inc. to Webcast, Live, at on July 12th
4. DATATRAK Announces Accreditation Program
5. DATATRAK Expands CDISC Registered Solutions Provider Standards
6. NTT DATA Licenses DATATRAK ONE™ for China
7. Catherine M. Burzik Elected as BD Director
8. Varian Equipment Selected to Equip New Cancer Center in Algeria and Enable More Advanced Radiotherapy Treatments for Patients
9. Cerulean Pharmas Lead Candidate Selected as a "Top 10 Oncology Project to Watch"
10. Acuo Technologies Selected in Department of Defense Award to Deliver Vendor Neutral Archive for U.S. Army and U.S. Navy Medical Commands
11. Greenphires ClinCard Technology Platform selected by top 5 pharmaceutical company for long-term global clinical trial
Post Your Comments:
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):